Skip to main content
Point/Counterpoint: Dordaviprone for diffuse midline glioma - A landmark approval or a premature step?
BRAF-altered glioma in adults and children: A Society for Neuro-Oncology (SNO) and European Society for Neuro-Oncology (EANO) consensus review on clinical management and future directions.
Tempered Optimism: Advances in the Precision Medicine Era for Pediatric Low-Grade Glioma.
The cellular and mutational origins of IDH mutant glioma.
Beyond base camp: PI3K/mTOR inhibition for the treatment of pediatric high-grade gliomas.
Salvage therapies for first relapse of SHH medulloblastoma in early childhood.
Germline analysis of an international cohort of pediatric diffuse midline glioma patients.
Applications of artificial intelligence and advanced imaging in pediatric diffuse midline glioma.
A Phase 2 PBTC Study of Selumetinib for Recurrent/Progressive Pediatric Low-Grade Glioma: Strata 2, 5, and 6 with Long-term Outcomes on Strata 1, 3, and 4.
Genetic ancestry superpopulations show distinct prevalence and outcomes across pediatric central nervous system tumors from the PBTA and PNOC.